ArticleCureus2025
A Rare Case of Methyldopa-Induced Hepatitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methyldopa is a centrally acting antihypertensive agent commonly used in the management of hypertension. It has been associated with rare but serious hepatotoxic effects. Methyldopa-induced hepatitis is an uncommon but potentially devastating adverse effect that can mimic autoimmune hepatitis (AIH) both clinically and histologically. This report presents the case of a 31-year-old woman with a history of hypertension who developed acute hepatitis following the initiation of methyldopa. The patient presented with fatigue, jaundice, and elevated liver enzymes approximately six weeks after starting therapy. Viral, autoimmune, and metabolic causes of hepatitis were excluded through comprehensive testing. Liver function normalized following the discontinuation of methyldopa, and the patient recovered fully, supporting a diagnosis of drug-induced liver injury (DILI). Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM), yielding a score of 9, indicating a 'highly probable' link between methyldopa and the observed hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.